Inhibition of Disease Progression in Hepatitis C-Infected Patients With Compensated Liver Cirrhosis.
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 09 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 27 Dec 2008 New trial record.